Larson Financial Group LLC Boosts Position in Edwards Lifesciences Co. (NYSE:EW)

Larson Financial Group LLC boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 199.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,391 shares of the medical research company’s stock after acquiring an additional 2,923 shares during the quarter. Larson Financial Group LLC’s holdings in Edwards Lifesciences were worth $290,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Kennedy Capital Management LLC bought a new stake in Edwards Lifesciences during the first quarter valued at about $2,440,000. B. Riley Wealth Advisors Inc. grew its holdings in Edwards Lifesciences by 80.4% during the first quarter. B. Riley Wealth Advisors Inc. now owns 21,065 shares of the medical research company’s stock valued at $2,013,000 after purchasing an additional 9,390 shares during the period. Tidal Investments LLC grew its holdings in Edwards Lifesciences by 54.7% during the first quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock valued at $2,890,000 after purchasing an additional 10,700 shares during the period. Plato Investment Management Ltd boosted its stake in shares of Edwards Lifesciences by 982.2% in the first quarter. Plato Investment Management Ltd now owns 7,521 shares of the medical research company’s stock worth $719,000 after acquiring an additional 6,826 shares during the period. Finally, Sanibel Captiva Trust Company Inc. boosted its stake in shares of Edwards Lifesciences by 3.7% in the first quarter. Sanibel Captiva Trust Company Inc. now owns 8,046 shares of the medical research company’s stock worth $769,000 after acquiring an additional 286 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $2,657,000 in the last ninety days. Corporate insiders own 1.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on EW shares. Royal Bank of Canada upped their price objective on Edwards Lifesciences from $75.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday. Canaccord Genuity Group dropped their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research note on Friday, October 25th. Piper Sandler dropped their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Finally, UBS Group dropped their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $75.90.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $72.06 on Thursday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $42.50 billion, a P/E ratio of 10.40, a P/E/G ratio of 4.01 and a beta of 1.12. The stock has a 50 day moving average price of $67.92 and a 200 day moving average price of $75.35.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the company earned $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.